|
WO2020247789A1
|
|
Processes for preparing aminopyrimidine compounds
|
|
WO2020247496A1
|
|
2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
|
|
WO2020205527A1
|
|
Treatment of cancer utilizing an identified adenosine fingerprint
|
|
WO2020185859A1
|
|
Treatment of oncogene-driven cancers
|
|
WO2020123772A1
|
|
Solid forms of a cd73 inhibitor and the use thereof
|
|
TW202033203A
|
|
Inhibitors of arg1 and/or arg2
|
|
WO2020046813A1
|
|
Cd73 inhibitors
|
|
AU2019312296A1
|
|
Pyridone A2R antagonists
|
|
SG11202100267TA
|
|
Solid forms of an azolopyrimidine compound
|
|
AU2019231781A1
|
|
Parenterally administered immune enhancing drugs
|
|
BR112020017604A2
|
|
ARGINASE INHIBITORS
|
|
WO2019161054A1
|
|
Dosing with an azolopyrimidine compound
|
|
WO2018213377A1
|
|
Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
|
|
CN110612100A
|
|
Quinazoline-pyridine derivatives for the treatment of diseases associated with cancer
|
|
TW201831467A
|
|
Azolopyrimidine for the treatment of cancer-related disorders
|
|
CN110022881A
|
|
The immunosuppressive inhibitor that CD73 is mediated
|
|
EP3518934A1
|
|
Inhibitors of adenosine 5'-nucleotidase
|
|
WO2017120508A1
|
|
Modulators of 5'-nucleotidase, ecto and the use thereof
|
